Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Royalty Pharma plc

Royalty Pharma plc (RPRX) Stock Overview

Explore Royalty Pharma plc’s financial performance, market position, analyst ratings, and future outlook.

RPRX●NASDAQ
HealthcareMedical - Pharmaceuticals
$57.97
$1.20(2.11%)
U.S. Market opens in 11h 44m

Royalty Pharma plc (RPRX)

Meyka AI Score

Z

Key Financials

Market Cap25.7B
P/E Ratio23.85
EPS (TTM)$5.25
ROE0.12%
Fundamental Analysis

AI Price Forecasts

1 Month$57.50
3 Months$62.42
1 Year Target$60.47

RPRX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Royalty Pharma plc (NASDAQ: RPRX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Royalty Pharma plc's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of RPRX on the NASDAQ shows an RSI of 52.62, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $60.47 for the NASDAQ listing.

Key metrics behind Royalty Pharma plc's NASDAQ-traded stock include a P/E ratio of 23.85 and a market capitalization of 25.7B. Combined with our AI analysis, these give both institutional and retail investors a clear view of RPRX on the NASDAQ.

Price Performance (NASDAQ: RPRX)

1-Day Change
2.11%
5-Day Change
-2.62%
1-Month Change
2.73%
3-Month Change
14.14%
6-Month Change
31.12%
Year-to-Date (YTD) Change
50.03%
1-Year Change
60.18%
3-Year Change
89.63%
5-Year Change
59.13%
All-Time (Max) Change
30.27%

Contact Information

https://www.royaltypharma.com
212 883 0200
110 East 59th Street, New York, NY, 10022

Company Facts

1,000 Employees
IPO DateJun 16, 2020
CountryUS
Actively Trading

Frequently Asked Questions